Both in Biotechnology
Denali Therapeutics vs Relay Therapeutics
Over the past year DNLI returned +38.3% and RLAY returned +154.3%; their daily moves had a correlation of 0.33.
DNLI +38.3% RLAY +154.3%Growth of $1, one year, split-adjusted
| Metric | DNLI | RLAY |
|---|---|---|
| Price | $21.25 | $17.65 |
| Market cap | $3.40B | $3.87B |
| Today | +9.25% | +1.20% |
| 1 month | +10.2% | −5.8% |
| 6 months | +4.1% | +36.6% |
| Year to date | +28.7% | +108.6% |
| 1 year | +38.3% | +154.3% |
| Revenue growth (YoY) | — | −48.3% |
| Gross margin | 97.4% | 100.0% |
| Net margin | −3539.2% | −23916.3% |
| P/E (TTM) | — | — |
| Price / sales | 942.5× | 373.7× |
| Net cash | $705.0M | $910.9M |
| Dividend yield | — | — |
| Volatility (60d) | 42.3% | 48.8% |
| Short % of float | 11.6% | 27.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).